Back to Search
Start Over
Pharmacodynamic assessment of ex-vivo canine T-lymphocyte proliferation: Responses to dexamethasone, cyclosporine, mycophenolic acid, and the active metabolite of leflunomide.
- Source :
-
Canadian journal of veterinary research = Revue canadienne de recherche veterinaire [Can J Vet Res] 2019 Oct; Vol. 83 (4), pp. 279-284. - Publication Year :
- 2019
-
Abstract
- A lack of understanding of specific immune defects underlying canine immune-mediated diseases hampers optimal therapy. Failure to tailor treatment to an individual's immune abnormality can result in lack of efficacy, secondary complications, added expense, and drug-potentiated adverse effects. We adopted a small-volume whole-blood flow cytometric assay to determine the effect of immunosuppressant drugs on T-lymphocyte proliferation. Using healthy dogs in this proof-of-principle study, we hypothesized that there would be dose-dependent suppression of T-lymphocyte proliferation in response to dexamethasone, cyclosporine, mycophenolic acid, and the active metabolite of leflunomide (A77 1726). Whole blood was collected from 6 healthy pet dogs and incubated for 4 d with or without the mitogens concanavalin A and lipopolysaccharide and with increasing concentrations of immunosuppressant. Samples were subsequently stained with viability dye and with antibodies against the pan-T-lymphocyte marker CD5 and the cell proliferation marker Ki67. Percentages of proliferating T-lymphocytes were determined by flow cytometry, and the 50% inhibitory concentration (IC <subscript>50</subscript> ) was calculated. Inhibition of T-lymphocyte proliferation by the panel of immunosuppressants was shown to be dose-dependent, with marked variability among the dogs. The mean IC <subscript>50</subscript> was 394.8 ± 871 (standard deviation) μM for dexamethasone, 18.89 ± 36.2 ng/mL for cyclosporine, 106.3 ± 157.7 nM for mycophenolic acid, and 3.746 ± 6.8 μM for A77 1726. These results support the use of this assay for detecting the efficacy of individual immunosuppressants used to diminish T-lymphocyte proliferation. In future, the assay may be applied to pet dogs with spontaneous immune-mediated disease to help tailor individual treatment.<br /> (Copyright and/or publishing rights held by the Canadian Veterinary Medical Association.)
- Subjects :
- Animals
Anti-Inflammatory Agents
Antibiotics, Antineoplastic pharmacology
CD5 Antigens genetics
CD5 Antigens metabolism
Cell Proliferation drug effects
Cell Survival
Cells, Cultured
Enzyme Inhibitors chemistry
Enzyme Inhibitors metabolism
Enzyme Inhibitors pharmacology
Immunosuppressive Agents pharmacology
Ki-67 Antigen genetics
Ki-67 Antigen metabolism
Leflunomide chemistry
Leflunomide pharmacology
T-Lymphocytes physiology
Cyclosporine pharmacology
Dexamethasone pharmacology
Dogs
Leflunomide metabolism
Mycophenolic Acid pharmacology
T-Lymphocytes drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1928-9022
- Volume :
- 83
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Canadian journal of veterinary research = Revue canadienne de recherche veterinaire
- Publication Type :
- Academic Journal
- Accession number :
- 31571728